MedWatch

FDA refuses to file Novo Nordisk application

The FDA has refused to start filing Novo Nordisk's application for an expanded marketing authorization for Ozempic in a higher dose.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk has received a Refusal to File letter from the US Food and Drug Administration (FDA) for its application for a version of Ozempic, which Novo Nordisk announces on Monday evening.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Latest news

See all jobs